Please login to the form below

Not currently logged in

Roche's T-DM1 activity in breast cancer "outstanding"

Improves survival by six months compared to GSK’s Tykerb/Tyverb

Roche building 

Updated results from a phase III trial of Roche's antibody-drug conjugate (ADC) T-DM1 in breast cancer indicate the drug helps extend survival by nearly six months, a result which one investigator in the trial has described as "truly outstanding".

T-DM1, which combines Roche's anti-HER2 antibody Herceptin (trastuzumab) with a chemotherapy payload, is due to reach the market next year and has already been tipped as a major seller for Roche with some analysts predicting peak revenues of up to $3.5bn a year.

The new data from the EMILIA study were presented yesterday at the European Society for Medical Oncology (ESMO) annual meeting, and come from a study involving patients with HER2-positive breast cancer whose disease had progressed despite earlier treatment with Herceptin.

Those treated with T-DM1 (trastuzumab emtansine) lived for 30.9 months on average, compared to 25.1 months for patients treated with capecitabine and GlaxoSmithKline's Tykerb/Tyverb (lapatinib), which is currently the only approved regimen in this setting.

The ADC was also associated with significantly fewer chemotherapy-related side effects, with severe reactions occurring in 41 per cent of the T-DM1 group versus 57 per cent of patients treated with the comparator regimen.

"These results are truly outstanding and will positively alter the outlook and outcomes for patients with HER2-positive breast cancer," said Professor Paul Ellis of King's College London, which served as one of the investigating sites for the EMILIA trial.

"For T-DM1 to offer such a significant survival benefit, while also improving the quality of patients' lives by reducing the side effects of chemotherapy, is a remarkable achievement, particularly as HER2-positive breast cancer is so difficult to treat in its advanced stages," he added.

Aside from the patient benefits, T-DM1 is an important product commercially for Roche as it starts to consider life after Herceptin's patent protection starts to expire in 2014, placing the drug's $6bn annual revenues - and 15 per cent of Roche's total turnover - at risk of generic competition.

Roche is developing additional products intended to protect its Herceptin franchise, including a subcutaneous formulation of the drug partnered with Halozyme Therapeutics which is scheduled for filing later this year.

2nd October 2012



Featured jobs

Subscribe to our email news alerts


Add my company
Gower Publishing Limited

Gower is recognised as one of the world's leading publishers of specialist business and management books and resources. Our publishing...

Latest intelligence

Pharma Marketing Summit: From ”why” to ”how” in multichannel communications
For the first time we’re sharing our observations of pharma conferences — kicking off with our delegates’ views of the Annual Pharma Marketing Summit in Berlin last month....
Access to orphan drugs for rare cancers in EU28
Revisiting Instagram for pharma
In pharma, Instagram usage is increasing because it offers so many benefits to engage with patients and HCPs...